Pfizer to Acquire CovX to Extend Biotherapeutics Investment
Acquisition Will Provide Innovative Biotherapeutics Technology Platform and Complementary Product Candidates in Oncology and Diabetes
NEW YORK -- Pfizer Inc announced today it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizerâ€™s biologic portfolio.
â€œThe acquisition of CovX is a further step in Pfizerâ€™s strategy to acquire and identify new product candidates that we can put into development, leveraging both Pfizerâ€™s expertise and that of world-class scientists charged with discovering and bringing in new compounds,â€ said Jeffrey Kindler, chairman and chief executive officer of Pfizer. â€œWith this deal, we are building on our recent announcement of a new Biotherapeutic and Bioinnovation Center based in California and led by Dr. Corey Goodman. We are looking for the best science wherever we can find it, with a special focus in our priority areas, such as biotherapeutics.â€
CovXâ€™s biotherapeutic platform is a technology that links therapeutic peptides to an antibody â€œscaffoldâ€. The peptide targets the disease while the antibody scaffold allows the peptide to remain in the body long enough to achieve therapeutic benefit. The technology thereby allows half-life extension and bioavailability to support optimal dosing regimens for peptide therapeutics.
As validation of this technology, CovX has generated three early- stage compounds, one diabetes and two oncology compounds, that are expected to further strengthen Pfizerâ€™s biologic pipeline portfolio.
Based in La Jolla, California, CovX will operate as a division of Pfizerâ€™s new Biotherapeutic and Bioinnovation Center.
â€œThis deal demonstrates Pfizerâ€™s ongoing commitment to build a competitive biotherapeutics enterprise through the acquisition of talented scientists, promising product candidates and a cutting edge technology platform,â€ said Dr. Corey Goodman, president of Pfizerâ€™s Biotherapeutic and Bioinnovation Center. â€œCovX scientists will remain in place, which reflects our decision to partner differently and maximize the productivity of the research initiatives underway outside of our walls.â€
"We are pleased to transition the CovX technology to Pfizer's Biotherapeutic and Bioinnovation group and are confident they have the vision and resources to scale the platform and realize the opportunity to make efficacious drugs which will make a difference in peoples' lives," stated Shehan Dissanayake, Chairman of CovX and CEO of Tavistock Life Sciences.
The acquisition is subject to customary closing conditions (including approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976), and is expected to close in the first quarter of 2008. Financial terms of the agreement were not disclosed.
DISCLOSURE NOTICE: The information contained in this release is as of December 18, 2007. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about an agreement by Pfizer to acquire CovX and about CovXâ€™s product candidates, technology platform and the potential benefits of that technology platform. Such information involves substantial risks and uncertainties including, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to approve any drug applications for such product candidates and any other product candidates that may be generated by CovXâ€™s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates; and competitive developments.
A further list and description of risks and uncertainties can be found in Pfizerâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and in its reports on Form 10-Q and Form 8-K.